Đang chuẩn bị liên kết để tải về tài liệu:
Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormonesensitive breast cancer

Mammalian target of rapamycin (mTOR) represents a key downstream intermediate for a myriad of oncogenic receptor tyrosine kinases. In the case of the insulin-like growth factor (IGF) pathway, the mTOR complex (mTORC1) mediates IGF-1 receptor (IGF-1R)-induced estrogen receptor alpha (ERα) phosphorylation/activation and leads to increased proliferation and growth in breast cancer cells. |